SCHEMBL191582

SCHEMBL191582

CCOC(=O)Cc1csc(Nc2cc(Sc3ccccc3)ccn2)n1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.57
▸ LMNA P02545 2/20 0.55
▸ TP53 P04637 1/20 0.55
▸ CYP2C9 P11712 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ MAPT P10636 3/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ GAA P10253 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24101409 0.79 TDP1 (0.65) ALDH1A1LMNATP53MAPTSMN1; SMN2
SCHEMBL191690 0.79 GCK (0.45) LMNATP53MAPTSMN1; SMN2GAA
SCHEMBL191333 0.78 MAPT (0.51) ALDH1A1LMNATP53CYP2C9CYP2C19
SCHEMBL190694 0.77 GCK (0.54) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL191398 0.72 GCK (0.46) ALDH1A1LMNAMAPTSMN1; SMN2TDP1
SCHEMBL190810 0.72 GAA (0.50) ALDH1A1LMNAMAPTSMN1; SMN2GAA
Hydrochloric Acid SCHEMBL190696 0.71 GAA (0.49) ALDH1A1LMNAMAPTSMN1; SMN2GAA
SCHEMBL191185 0.71 ALDH1A1 (0.53) ALDH1A1LMNACYP2C19MAPTSMN1; SMN2
SCHEMBL191430 0.71 LMNA (0.46) ALDH1A1LMNATP53CYP2C9CYP2C19
SCHEMBL192053 0.71 GCK (0.47) ALDH1A1LMNATP53MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 — — EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 — — US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 — — US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 — — US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 — — US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 — — US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 — — US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 — — EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 ALDH1A1 1869/4885LMNA 1829/4885TP53 3820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback